Medsenic SAS, a biopharmaceutical company dedicated to the treatment of autoimmune diseases with arsenic derivatives, announced today that it raised funds from two investment actors, Alsace Capital (Cap Innov’Est) and Fa Dièse (Fa Dièse 3). The CNRS (French Centre National de la Recherche Scientifique), through its subsidiary Fist SA is also becoming shareholder of the company. Others private investors are participating, Medsenic still being significantly supported by its existing private investors.
The company first targets the so-called orphan Graft vs Host Disease (GvHD). There is as of today no satisfactory treatment, and Medsenic ambitions to bring to patients a solution with its concept of arsenic trioxide positive regulatory action in autoimmunity.
In addition to conclusive animal data, the company has demonstrated the potential of arsenic trioxide in human autoimmunity with Phase IIa results in severe Systemic Lupus Erythematosus, presented at the ACR conference in San Francisco in November 2015 by Prof. Mohamed Hamidou, Chief of Internal Medicine in the Main Teaching Hospital Hôtel-Dieu, in Nantes (France).